Merck CEO Stresses Need For ‘Fair Return’ On COVID-19 Interventions
Also Shares Views On US Pricing Moves
Merck & Co’s chief executive shares views on the need for “reasonable” returns on COVID-19 therapeutics and vaccines, and on the future US pricing environment, at the USAIC summit.
You may also be interested in...
Biocon chair believes new perspectives on regulatory science and processes emerging from the US's "Warp Speed" efforts to accelerate COVID-19 vaccines have potential for wider application, although Regeneron's president urges caution around relying only on small studies to advance repurposed drugs.
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.